{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:13Z","timestamp":1790678593656,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T00:00:00Z","timestamp":1410480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T00:00:00Z","timestamp":1410480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/leu.2014.272","type":"journal-article","created":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T06:45:36Z","timestamp":1410504336000},"page":"2292-2299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status"],"prefix":"10.1038","volume":"28","author":[{"given":"M","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Obstfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ziermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Eigendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,12]]},"reference":[{"key":"BFleu2014272_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342\u2013350.","journal-title":"Lancet"},{"key":"BFleu2014272_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","volume":"101","author":"T Bumm","year":"2003","unstructured":"Bumm T, M\u00fcller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941\u20131949.","journal-title":"Blood"},{"key":"BFleu2014272_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1080\/10428190410001723278","volume":"45","author":"M Loriaux","year":"2004","unstructured":"Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197\u20132203.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014272_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/sj.leu.2400642","volume":"11","author":"L Fayad","year":"1997","unstructured":"Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767\u2013771.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3324\/haematol.12793","volume":"93","author":"A Fabarius","year":"2008","unstructured":"Fabarius A, Giehl M, Rebacz B, Kr\u00e4mer A, Frank O, Haferlach C et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC\/ABL inhibitor dasatinib. Haematologica 2008; 93: 1145\u20131154.","journal-title":"Haematologica"},{"key":"BFleu2014272_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/cncr.22936","volume":"110","author":"MW Deininger","year":"2007","unstructured":"Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007; 110: 1509\u20131519.","journal-title":"Cancer"},{"key":"BFleu2014272_CR7","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110: 2991\u20132995.","journal-title":"Blood"},{"key":"BFleu2014272_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cancergen.2012.09.003","volume":"205","author":"SE Lee","year":"2012","unstructured":"Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet 2012; 205: 563\u2013571.","journal-title":"Cancer Genet"},{"key":"BFleu2014272_CR9","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","volume":"108","author":"C Kovitz","year":"2006","unstructured":"Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J . Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811\u20132813.","journal-title":"Blood"},{"key":"BFleu2014272_CR10","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/leu.2011.280","volume":"26","author":"G Georgiou","year":"2012","unstructured":"Georgiou G, Efthymiou A, Vardounioti I, Boutsikas G, Angelopoulou MK, Vassilakopoulos TP et al. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib. Leukemia 2012; 26: 824\u2013826.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2014272_CR12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA . Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158\u2013163.","journal-title":"Blood"},{"key":"BFleu2014272_CR13","first-page":"1163","volume":"7","author":"WH Raskind","year":"1993","unstructured":"Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ . Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993; 7: 1163\u20131167.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR14","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1038\/leu.2008.231","volume":"22","author":"NC Cross","year":"2008","unstructured":"Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008; 22: 1975\u20131989.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506\u2013510.","journal-title":"Nature"},{"key":"BFleu2014272_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090\u20131098.","journal-title":"N Engl J Med"},{"key":"BFleu2014272_CR17","doi-asserted-by":"publisher","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","volume":"4","author":"M Jan","year":"2012","unstructured":"Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118.","journal-title":"Sci Transl Med"},{"key":"BFleu2014272_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328\u2013333.","journal-title":"Nature"},{"key":"BFleu2014272_CR19","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/leu.2014.211","volume":"28","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Majeti R . Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 2014; 28: 2276\u20132282.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2014272_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFleu2014272_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"T Ernst","year":"2008","unstructured":"Ernst T, Erben P, M\u00fcller MC, Paschka P, Schenk T, Hoffmann J et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008; 93: 186\u2013192.","journal-title":"Haematologica"},{"key":"BFleu2014272_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1373\/clinchem.2013.204099","volume":"59","author":"J Rinke","year":"2013","unstructured":"Rinke J, Sch\u00e4fer V, Schmidt M, Ziermann J, Kohlmann A, Hochhaus A et al. Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. Clin Chem 2013; 59: 1238\u20131250.","journal-title":"Clin Chem"},{"key":"BFleu2014272_CR24","doi-asserted-by":"publisher","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi Y, Sims GE, Murphy S, Miller JR, Chan AP . Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 2012; 7: e46688.","journal-title":"PLoS ONE"},{"key":"BFleu2014272_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248\u2013249.","journal-title":"Nat Methods"},{"key":"BFleu2014272_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53\u201359.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/10428199309047861","volume":"11","author":"NC Cross","year":"1993","unstructured":"Cross NC, Feng L, Bungey J, Goldman JM . Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11: 39\u201343.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014272_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","volume":"13","author":"M Emig","year":"1999","unstructured":"Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825\u20131832.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.leu.2404983","volume":"22","author":"MC M\u00fcller","year":"2008","unstructured":"M\u00fcller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96\u2013102.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR30","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, M\u00fcller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trails. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2014272_CR31","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496\u20132506.","journal-title":"N Engl J Med"},{"key":"BFleu2014272_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722\u2013726.","journal-title":"Nat Genet"},{"key":"BFleu2014272_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL . The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599\u2013612.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2014272_CR34","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","volume":"111","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548\u20132553.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014272_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11\u201324.","journal-title":"Cancer Cell"},{"key":"BFleu2014272_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronn\u00e9 L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25\u201338.","journal-title":"Cancer Cell"},{"key":"BFleu2014272_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2011","unstructured":"Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44: 23\u201331.","journal-title":"Nat Genet"},{"key":"BFleu2014272_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/ng.2413","volume":"44","author":"L Busque","year":"2012","unstructured":"Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179\u20131181.","journal-title":"Nat Genet"},{"key":"BFleu2014272_CR39","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","volume":"95","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase A, Zoi K, Waghorn K, Hidalgo-Curtis C, Score J et al. Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms. Haematologica 2010; 95: 1473\u20131480.","journal-title":"Haematologica"},{"key":"BFleu2014272_CR40","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/sj.leu.2403931","volume":"19","author":"S Corm","year":"2005","unstructured":"Corm S, Biggio V, Roche-Lestienne C, La\u00ef JL, Yakoub-Agha I, Philippe N et al. Coexistence of AML1\/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. Leukemia 2005; 19: 1991\u20131992.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2010.65","volume":"24","author":"J Boultwood","year":"2010","unstructured":"Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010; 24: 1139\u20131145.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557\u2013560.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR43","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011; 117: e198\u2013e206.","journal-title":"Blood"},{"key":"BFleu2014272_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/leu.2010.236","volume":"25","author":"S Soverini","year":"2011","unstructured":"Soverini S, Score J, Iacobucci I, Poerio A, Lonetti A, Gnani A et al. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia 2011; 25: 178\u2013181.","journal-title":"Leukemia"},{"key":"BFleu2014272_CR45","first-page":"139","volume":"7","author":"M Deininger","year":"2013","unstructured":"Deininger M . Recent advances in understanding chronic myeloid leukemia biology. Hematol Edu 2013; 7: 139\u2013146.","journal-title":"Hematol Edu"},{"key":"BFleu2014272_CR46","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014272","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:09:01Z","timestamp":1648742941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["BFleu2014272"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.272","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,12]]},"assertion":[{"value":"25 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, TH and CH are part owners of the MLL Munich Leukemia Laboratory. AK is employed by the MLL Munich Leukemia Laboratory and has received honoraria from Roche. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}